Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 7/20 | 0.62 |
| ▸ | FPR2 | P25090 | 5/20 | 0.62 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19972322 | 0.85 | FPR1 (0.67) | FPR1FPR2KDM1AALDH1A1EPHX2 | |
| SCHEMBL20001240 | 0.82 | FPR1 (0.64) | FPR1FPR2PDE4B | |
| SCHEMBL19988375 | 0.82 | FPR1 (0.64) | FPR1FPR2PDE4B | |
| SCHEMBL18596569 | 0.79 | KDM1A (0.76) | KDM1APDE4BEPHX2MAOBMAOA | |
| SCHEMBL15091431 | 0.79 | KDM1A (0.76) | KDM1APDE4BEPHX2MAOBMAOA | |
| SCHEMBL15091433 | 0.79 | KDM1A (0.76) | KDM1APDE4BEPHX2MAOBMAOA | |
| SCHEMBL19988380 | 0.78 | FPR1 (0.63) | FPR1FPR2KDM1APDE4BALDH1A1 | |
| SCHEMBL20001277 | 0.78 | FPR1 (0.63) | FPR1FPR2KDM1APDE4BALDH1A1 | |
| SCHEMBL19988741 | 0.77 | FPR1 (0.80) | FPR1FPR2 | |
| SCHEMBL19972388 | 0.77 | FPR1 (0.74) | FPR1FPR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10265310-B2 | 6-membered cyclic amines or lactames substituted with urea and phenyl | Grünenthal GmbH (DE) | 2019-04-23 | — | — | US | disclosed |
| WO-2018054549-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | Grünenthal GmbH (DE) | 2018-03-29 | — | — | WO | disclosed |
| US-20180078541-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | Grünenthal GmbH (DE) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078541-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | FPR2, FPR1, FPR3 | FPR1 2/4885FPR2 1/4885KDM1A 4514/4885 |
| US-10265310-B2 | 6-membered cyclic amines or lactames substituted with urea and phenyl | FPR2, FPR1, FPR3 | FPR1 2/4885FPR2 1/4885KDM1A 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.